To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Down syndrome (DS) is the most common chromosomal abnormality in live newborn children and results from acquisition of either an intact extra copy of chromosome 21 or a portion of it, the so-called DS critical region. Multiple benign hematologic abnormalities are common in newborns with DS and undergo spontaneous resolution within the first month of life. Transient abnormal myelopoiesis (TAM), an unusual myeloproliferative condition restricted to DS, is present at birth in a minority of infants with DS. Although usually clinically indolent and spontaneously remitting, TAM may be associated with significant morbidity secondary to hepatic fibrosis. In a subset of cases, TAM either progresses to or recurs as myeloid leukemia of DS (ML-DS) during the first three years of life, typically with morphologic and immunophenotypic evidence of megakaryocytic differentiation. Older children with DS are also at increased risk for development of acute leukemia, usually B-lymphoblastic leukemia (B-ALL). In this chapter, the benign hematologic abnormalities of DS are discussed. In addition, the clinical, laboratory, and pathologic findings in TAM and the pathogenetically related AMKL of DS are discussed in detail with an emphasis on their differential diagnosis. Finally, the pathogenetic and pathologic features of B-ALL of DS are discussed.
Acute myeloid leukemia (AML) is a group of clonal malignancies of the bone marrow and peripheral blood. Advances in our understanding of the genetic abnormalities responsible for the development of AML together with the rapidly evolving development of therapeutics that specifically target the underlying genetic lesions have necessitated further refinements in the classification of AML. This is reflected in the recently published International Consensus Classification of AML in which genetically based categorization of AMLs is incorporated to a greater extent than in previous World Health Organization classification schemes, with the goals of improving diagnostic precision, providing more meaningful prognostic information and identifying those patients for whom targeted therapeutics may be beneficial. Genetically defined AMLs account for a higher percentage of cases in children than in adults, and some AML subtypes occur solely in children. This chapter provides an overview of childhood AML, with an emphasis on those entities that are more common or restricted to the pediatric population. Discussion of each AML subtype includes a summary of the molecular pathogenesis and description of the relevant clinical, laboratory, pathologic, and molecular diagnostic features, with an emphasis on differential diagnosis and appropriate utilization of ancillary testing during the diagnostic workup of pediatric AML.
This chapter describes normal megakaryocytic maturation and the dynamic antigenic changes associated with megakaryocytic differentiation. Common markers used to define the megakaryocytic lineage are highlighted. For acute megakaryoblastic leukemia (AMKL), three distinct clinical groups are discussed, and common chromosomal translocations associated with AMKL are described. The immunophenotypes associated with each AMKL subtype are addressed in detail. For the differential diagnosis, non-neoplastic (such as platelet adhesion) and neoplastic processes (such as acute erythroid leukemia and non-hematopoietic tumors) are included.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.